[1]

Fanning E, Inder WJ, Mackenzie E. Radioiodinetreatment for Graves' disease: a 10-year Australian cohort study[J/OL]. BMC Endocr Discord, 2018, 18(1): 94[2020-03-22]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292026. DOI: 10.1186/s12902-018-0322-7.
[2] Liu M, Jing DQ, Hu JS, et al.  Predictive factors of outcomes in personalized radioactive iodine 131I treatment for Graves' disease[J]. Am J Med Sci, 2014, 348(4): 288-293.   doi: 10.1097/MAJ.0000000000000288
[3] Xing YZ, Zhang K, Jin G.  Predictive factors for the outcomes of Graves' disease patients with radioactive iodine 131I treatment[J]. Biosci Rep, 2020, 40(1): BSR20191609-.   doi: 10.1042/BSR20191609
[4] 张王峰, 马友凤, 周梅, 等.  甲亢131碘治疗后早发甲减患者临床转归的分析[J]. 广西医科大学学报, 2016, 33(2): 320-322.   doi: 10.16190/j.cnki.45-1211/r.2016.02.039
Zhang WF, Ma YF, Zhou M, et al.  Analysis of clinical outcomes of early hypothyroidism after 131I treatment of hyperthyroidism[J]. J Guangxi Med Univ, 2016, 33(2): 320-322.   doi: 10.16190/j.cnki.45-1211/r.2016.02.039
[5] Honda A, Uchida T, Komiya K, et al.  Relationship between the effectiveness of inorganic iodine and the severity of Graves thyrotoxicosis: a retrospective study[J]. Endocr Pract, 2017, 23(12): 1408-1413.   doi: 10.4158/EP-2017-0044
[6] 蒋宁一, 林岩松, 关海霞, 等.  131I治疗格雷夫斯甲亢指南(2013版)[J]. 标记免疫分析与临床, 2014, 21(1): 92-104.   doi: 10.11748/bjmy.issn.1006-1703.2014.01.030
Jiang NY, Lin YS, Guan HX, et al.  Guideline of 131I treatment of Graves' hyperthyroidism(2013)[J]. Labeled Immunoassays & Clin Med, 2014, 21(1): 92-104.   doi: 10.11748/bjmy.issn.1006-1703.2014.01.030
[7] Wiersinga WM.  Graves' disease: can it be cured?[J]. Endocrinol Metab (Seoul), 2019, 34(1): 29-38.   doi: 10.3803/EnM.2019.34.1.29
[8]

Wong KK, Shulkin BL, Gross MD, et al. Efficacy of radioactive iodine treatment of Graves' hyperthyroidism using a single calculated 131I dose[J/OL]. Clin Diabetes Endocrinol, 2018, 28(4): 20[2020-03-22]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6260735. DOI: 10.1186/s40842-018-0071-6.
[9] Wolfgang R, Niklas AM, Max M.  Multispectral optoacoustic tomography of benign and malignant thyroid disorders: a pilot study[J]. J Nucl Med, 2019, 60(10): 1461-1466.   doi: 10.2967/jnumed.118.222174
[10] Léger J, Carel JC.  Diagnosis and management of hyperthyroidism from prenatal life to adolescence[J]. Best Pract Res Clin Endocrinol Metab, 2018, 32(4): 373-386.   doi: 10.1016/j.beem.2018.03.014
[11] Leslie WD, Ward L, Salamon EA, et al.  A randomized comparison of radioiodine doses in Graves' hyperthyroidism[J]. J Clin Endocrinol Metab, 2003, 88(3): 978-983.   doi: 10.1210/jc.2002-020805
[12] Canto AU, Dominguez PN, Jimeno CA, et al.  Comparison of fixed versus calculated activity of radioiodine for the treatment of Graves' disease in adults[J]. Endocrinol Metab (Seoul), 2016, 31(1): 168-173.   doi: 10.3803/EnM.2016.31.1.168
[13] Dong Q, Liu X, Wang F, et al.  Dynamic changes of TRAb and TPOAb after radioiodine therapy in Graves' disease[J]. Acta Endocrinol (Buchar), 2017, 13(1): 72-76.   doi: 10.4183/aeb.2017.72
[14] 傅宏亮, 杜学亮, 李佳宁, 等.  计算剂量方案行格雷夫斯病甲状腺功能亢进放射性碘治疗的疗效分析[J]. 上海交通大学学报: 医学版, 2014, 34(7): 1039-1042.   doi: 10.3969/j.issn.1674-8115.2014.07.016
Fu HL, Du XL, Li JN, et al.  Analysis of therapeutic effect of empirically calculated dose of radioiodine therapy on hyperthyroidism of Graves disease[J]. J Shanghai Jiaotong Univ (Med Sci), 2014, 34(7): 1039-1042.   doi: 10.3969/j.issn.1674-8115.2014.07.016
[15] Kahaly GJ, Bartalena L, Heqedüs L, et al.  2018 European thyroid association guideline for the management of Graves' hyperthyroidism[J]. Eur Thyroid J, 2018, 7(4): 167-186.   doi: 10.1159/000490384